Clinical outcome of autologous mononuclear cells transplantation for spinal cord injury: a systematic review and meta-analysis

Hamid Reza Aghayan¹, Babak Arjmand², Mohsen Yaghoubi³, Maziar Moradi-Lakeh⁴
Homa Kashani⁵, Farhad Shokraneh⁶

Abstract

Background: Cell-based therapies can be used to treat neurological diseases and spinal cord injuries. The aim of this study was to assess the clinical outcome of bone marrow derived mononuclear cells (BM-MNCs) transplantation in patients with spinal cord injuries.

Methods: Following a systematic review to detect clinical intervention studies, a meta-analysis was done for pooling data to estimate the outcome of BM-MNCs transplantation. The percentage of the patients with improved ASIA scale from one grade to a higher grade was defined as the main outcome. By considering the study design and outcome measurement, two reviewers independently extracted the data.

Results: Eight relevant primary studies were found; seven qualified studies, with a combined total of 328 patients were assessed by meta-analysis, including 314 ASIA-A, 13 ASIA-B, 94 cervical, 227 thoracic and 60 acute injuries. The percentage of the patients’ improvement was tested by meta-analysis through random and fixed models. The overall percentage of all patients’ improved ASIA scale after a one-year follow-up (95% CIs) was 43 (0.27-0.59).

Conclusion: Data from published trials revealed that encouraging results were achieved by autologous BM-MNCs for the treatment of spinal cord injury. However, the number of clinical trials included in the systematic review was too limited to reach a definite conclusion. More qualified clinical trials with standardized methods are needed to truly justify the outcome of this therapeutic modality in SCI patients.

Keywords: Cell Transplantation, Bone Marrow Derived Mononuclear Cells, Spinal Cord Injury.

Cite this article as: Aghayan H.R, Arjmand B, Yaghoubi M, Moradi-Lakeh M, Kashani H, Shokraneh F. Clinical outcome of autologous mononuclear cells transplantation for spinal cord injury: a systematic review and meta-analysis. Med J Islam Repub Iran 2014 (14 October). Vol. 28:112.

Introduction

Spinal Cord Injury (SCI) occurs with a worldwide incidence of 15–40 cases per million people annually (1). Epidemiological data concerning the global prevalence of SCI is inaccessible. Also, it is appraised that more than 130,000 patients suffer from SCI per year. The mean age of spinal cord injury patients is 30 years, demonstrating that it disables persons in the prime of their lives. The high rate of incidence in adolescent groups is reasoned to the road accidents and sports related damages (2). Up to now, there is no cure available for these individuals, and SCI usually leads to important life-long disability (3,4). Despite a
lack of internationally accepted scientific evidences, cell-based therapies offer great promise for many currently intractable conditions including neurological disorders. Frequently mentioned targets include neurological diseases and spinal cord injury (5). Different cell types have been studied in animal models and clinical trials. The bone marrow derived from mononuclear cells (BM-MNCs) is extracted from the bone marrow directly, or it is derived via mobilization into the peripheral blood using granulocyte colony-stimulating factor (GCSF) (6). BM-MNCs are the most common cell population used in neuropathologic insults. These cells have many advantages including easy and rapid isolation with minimal manipulation, ample cell number, low processing costs and a minimally invasive bone marrow harvest procedure (7). BM-MNCs have been reported to promote repair and regeneration of nervous tissue within the central and peripheral nervous system (8). It seems that BM-MNC can facilitate recovery from SCI by promoting remyelinating spared white matter tracts or intensifying axonal growth (9). However, the transdifferentiation of BM cells into myelin cells is an area of great controversy, and there is no convulsive evidence that these cells do this process without extensive genetic and epigenetic manipulation.

Although the results of pre-clinical studies recommend that BM-MNCs could be used as a potential therapy for SCI, (10) they have not clearly indicated whether these cells have therapeutic advantages in SCI patients. Since BM-MNCs transplantation has been considered as a novel intervention in clinical trials for SCI, it has not been scientifically proven to be safe and effective. This systematic review investigates the clinical outcome of BM-MNCs transplantation for patients with traumatic SCI. The objective was to determine whether BM-MNC transplantation can increase ASIA scale, which is a valid and useful tool for determining the function maintained by a patient after suffering from spinal cord injuries (11).

**Methods**

**Search Strategy**

We performed PICOS framework (Determining patient, problem or population, intervention, comparison and outcome) to define the main concepts of the research questions.

**Patient:** People with Spinal Cord Injury

**Intervention:** Bone Marrow Transplantation

**Comparison:** No Treatment

**Outcome:** Improvement in the ASIA Score

Computerized databases were searched on 28 October 2012. To retrieve both original and secondary related studies, we used a sensitive librarian-assisted search strategy in the last available version of the three following databases at the time of the search: MEDLINE via Ovid SP (1948 to 28 October 2012), EMBASE via Ovid SP (1989 to 27 October 2012) and CENTRAL via Ovid SP (September 2012). The search was limited to the English language. Search was updated on May 2013; however, no new records were found. Because of the low number of results in the primary search, we applied a sensitive search strategy to retrieve a suitable number of records and minimize any missing of possible related records. Therefore, we included only problem and intervention in PICOS structure of the formulated question to achieve higher sensitivity, and we did not limit our results to humans and particular types of study designs. The database search was completed with a search of RCTs (Randomize Control Trials) registries and reviewing of the reference lists of the included studies along with citations. The following search strategy was developed for MEDLINE via Ovid SP and was then adapted to other resources:

**I: Spinal Cord Injury**

1. exp spinal cord injuries/
2. (((spinal or central or cervical or medulla$) adj3 cord) adj3 (trauma$ or injur$ or syndrome or lesion or compress$ or pinch$ or trans?) sect$ or transect$ or lac-
H.R. Aghayan, et al.

I: Search strategy

1. (transplant$ or transplanted$ or transplan$ or transp$ or transplant$ or graft$ or autograft$ or allograft$ or autograft$ or homograft$ or xenograft$ or (stem cell$ or cord$ or umbilical$ or placental$ or fetal$) adj (transplant$ or graft$ or purg$ or (cell adj (transfer or remov$)) or rescu$ or transfs$)).tw,ot.
2. myelopath$.tw,ot.
3. (spinal trans?section).tw,ot.
4. (transverse lesion).tw,ot.
5. (autonom$ adj3 (dysreflexia$ or hyper?reflexia$)).tw,ot.
6. myelopathy.tw,ot.
7. (conus medullaris syndrome).tw,ot.
8. or/1-7

II: Bone Marrow Transplantation

9. bone marrow transplantation/
10. bone marrow purging/
11. exp stem cell transplantation/ and (bone marrow).tw,ot.
12. ((bone marrow) adj6 (transplant$ or graft$ or purg$ or (cell adj (transfer or remov$)) or rescu$ or transfs$)).tw,ot.
13. (((stem cell) or cord) adj (transplant$ or graft$ or purg$ therap$)) and (bone marrow).tw,ot.
14. or/9-13

III: I and II

15. 8 and 14

Inclusion criteria

All those clinical trials which measured neurological assessment as ASIA scale pre- and post-transplantation or those which included participants with traumatic SCI (cervical or thoracic level) as well as ASIA (American Spinal Injury Association) scale A or B at baseline were included in this review.

Exclusion criteria

Animal studies were excluded in this review. Other studies that did not report ASIA score as a clinical outcome along with those studies which considered other types of bone marrow derived cells or mixed cell population (BM-MSCs + BM-MNCs) as well as case reports were excluded from this review.

Subgroups

This review determined three subgroups on the basis of impairment scale, level of injury and duration of SCI. The ICCP (International Campaign for Cures for spinal cord injury Paralysis) panel guideline men-

tioned that these variables can influence spontaneous recovery rate. However, a clinical trial considering ASIA -A patients showed less spontaneous improvement over time (18). This review analyzed patients with complete and incomplete ASIA separately. In addition, the duration of SCI in terms of acute and chronic injuries was defined, and the level of injury was divided into cervical and thoracic injury.

Data extraction

Data extraction was conducted by two independent researchers of the study (M-Y and HR-A). Data pertaining to the number of the enrolled patients, injury types and levels, type and dose of cell transplants, duration of the follow ups and clinical outcomes with confidence intervals were extracted from the papers. We defined the percentage of the patient’s improvement from ASIA scale A to B/C or ASIA scale B to C/D as a clinical outcome after a one-year follow-up. It should be noted that a clinical trial with a small size effect may need a more accurate outcome measure such as a statistically mean change in the motor and sensory scores (19). Therefore, we reported the mean change of the motor score and sensory score (light touch and Pinprick) at the time of the transplant and at the end of the last follow-up as a functional outcome in three studies (10, 14, 16). These studies reported the details of motor and sensory scores along with the ASIA scale. The confidence interval and lower and upper limits were not reported directly, so we calculated and recorded them using other indices which were based on formulas.

Synthesis of the results

Meta-analysis was performed using the STATA statistical package version 11. First, we assessed the heterogeneity between the studies by Chi-squared test (P<0.1 as meaningful). We used random or fixed model for pooling the percentage of improvement and 95% confidence intervals in case of heterogeneous and homogenous cases, respectively. In addition, p-values
less than 0.05 were regarded significant.

The subgroups were determined based on the patients’ injury type (impairment scale, level and stage of injury). ASIA-A, ASIA-B, cervical, thoracic and acute patients were regarded as subgroups. Chronic subgroups were excluded from the meta-analysis because this subgroup included only one study. Due to the different characteristics of each subgroup after excluding the chronic group from the analysis, we had to pool the data from the acute group separately, not acute versus chronic; otherwise, the pooled estimate would have led to an inability in reaching a firm conclusion about the potential benefit of a candidate therapy.

Results

Study selection

The search identified 594 studies, among which 122 were duplicates (Fig. 1). Titles and abstracts of the obtained articles were assessed for relevancy by two researchers independently (M-Y, HR-A). Any disagreements were resolved by consensus or discussion with the authors. After screening the titles and abstracts, 17 studies were determined as eligible (BM-MNC transplantation, in which the standard neurological outcome had been reported). The full texts of the relevant articles were checked for eligibility criteria after investigating the full reports, and consequently nine studies were excluded. Finally, eight studies with a total number of 337 participants were evaluated to find the outcome of BM-MNC transplantation in patients with SCI (Table 1) (12–17). Moreover, seven studies were included in the meta-analysis.

With respect to the quality assessment, all clinical trials had a high risk of bias; specifically, seven of eight studies were non-randomized. Moreover, the details of randomization methods were unclear in the remaining studies. Since it is difficult to
blind therapists to use stem cell transplant, none of the clinical trials reported allocation concealment or blinding. With regards to the incomplete data, all trials had a low risk of bias. Overall, two out of 337 patients failed to participate in the follow-up durations.

**Meta analysis**

We ended up with eight studies in the systematic review, one of which was excluded from our analysis because of 100% improvement (No variation) (13). The remaining studies had a combined total of 328 patients. Our findings revealed a considerable heterogeneity among these studies ($X^2=36.1$, $p<0.0001$, $I^2=83.6\%$). Also, the results of the meta-analysis using a random model revealed an estimate of 0.428 (95% CI = (0.268, 0.589)) for the proportion of the improvement which was statistically significant ($p<0.0001$). Although the meta-analysis in the subgroups of patients with BM-MNCs transplantation in ASIA-B at baseline resulted in homogeneity between the studies, a considerable heterogeneity

| Reference         | Number of cases | Sub groups | Dosage BM-MNC *10⁶ | All | A* | B** | C ³ | T ⁴ | Ac ⁵ | Ch vô | CG ⁶ | Follow up |
|-------------------|-----------------|------------|-------------------|-----|----|-----|-----|-----|------|------|------|-------|----------|
| Attar et al, 2011[12] | Patient = 4/ Control = 0 | All patients ASIA A, thoracic and acute. | 19.6-275 | 75 | 75 | 0 | 0 | 75 | 75 | 0 | - | 1 year Follow-up. 3 patient of 4 show neurological improvement and none of the patients suffered from any side effects or complications. |
| Deda et al, 2009[13] | Patient = 9/ Control = 0 | All patients ASIA A 6 cervical and 3 thoracic, all patients chronic. | 20-67 | 100 | 100 | 0 | 100 | 100 | 0 | 100 | - | 1 year Follow-up. All of the patients showed improved neurological function without any serious complications. |
| Geffner et al, 2008[14] | Patient = 6/ Control = 0 | 5 patients ASIA A and 1 ASIA B All thoracic, 4 acute and 2 chronic. | 400 | 83 | 80 | 100 | 0 | 83 | 75 | 100 | - | 1 year Follow-up. 7 patients of 8 show neurological improvement, all patients showed increased bladder control/sensation and had improved quality of life scores. No cases of tumorformation, infection, or increased pain. |
| JK Jung et al, 2011[11] | Patient = 19/ Control = 0 | 17 patient ASIA A and 2 patient ASIA B 10 patient cervical and 9 thoracic, all patients acute. | 200 | 47 | 52 | 50 | 50 | 55 | 47 | 0 | - | 3-11 month Follow-up. The ASIA scale of the group had improved in 7 patients from grade A to C, in 3 patients from grade A to B, and in 1 patient from B to C. |
| Kumar et al, 2009[15] | Patient = 240/ Control = 0 | 233 patients ASIA A and 7 patients ASIA B 44 cervical and 196 thoracic and all chronic. | 1 | 31 | 31 | 42 | 34 | 31 | 0 | 31 | - | 3-21 month Follow-up. One-third of spinal cord injury patients had improved motor and sensory change happened in 32.6% of patients. No complications or side effect were reported, except for minor reversible complaints. |
Clinical outcome of autologous mononuclear cells transplantation…

Table 1. Published BM-MNCs Transplantation Trials for SCI

| Study Reference | Participant | Treatment group | Dosage BM-MNC *10⁶ | All | A* | B** | C* | T* | Ac* | Ch* | CG* | Follow up |
|-----------------|-------------|-----------------|-------------------|-----|----|-----|----|----|-----|-----|-----|--------|
| Park et al 2005[10] | Patient= 5 Control= 0 | All patients ASIA A cervical and acute. | 1980 | 80 | 80 | 0 | 80 | 0 | 80 | 0 | - | 6-18 month Follow-up. Five of the six patients showed improved neurological function. No serious complications, that is, increased mortality and morbidity were reported. |
| Sykova et al 2006[16] | Patient= 19 Control= 0 | 15 patients ASIA A, 4 ASIA B, 12 cervical and 8 thoracic, 5 acute and 14 chronic | 5530 | 10 | 6 | 25 | 16 | 0 | 33 | 0 | - | 6-12 month Follow-up. 2 patients lost to follow-up and 2 of the 19 patients showed an improved ASIA score. No serious complications were reported. |
| Yoon et al 2007[17] | Patient= 35 Control= 13 | All patients ASIA A, 23 cervical and 12 thoracic; 23 acute and 12 chronic | 200 | 20 | 20 | 0 | 17 | 25 | 21 | 0 | 7 | 10 month Follow-up. 7 patients of 35 patients in transplant group and one of 13 patients in control group showed improved neurological function. No serious complications, sepsis, or wound infections were reported. |

A* = ASIA A patient, B** = ASIA B patient, C* = Cervical level, T* = Thoracic Level, Ac* = Acute, Ch* = Chronic, CG* = Control Group.

was observed among them by considering ASIA-A, acute, cervical and thoracic subgroups of patients. Table 2 demonstrates the number of patients in each subgroup and the estimated pooled proportion of improvement as well as the results of heterogeneity tests. The meta-analysis revealed that the percentage of patient improvement (95% CIs) was 0.41 (0.25-0.58) for patients with ASIA scale A at the baseline, 0.37 (0.11-0.63) for patients with ASIA scale B at the baseline, 0.53 (0.31-0.74) for patients in acute stage, 0.43 (0.18-0.67) for patients with cervical injury level and 0.50 (0.28-0.72) for patients with thoracic injury level.

ASIA impairment scale in SCI clinical trial was considered as a clinical outcome. However, considering the functional outcome...
come (motor and sensory scores) might also be useful in these trials. As a result of the mean change of the motor and sensory scores, three qualified studies conducted on 32 patients were assessed (Table 3). In the other trials, the details of the scores were not reported.

**Discussion**

The aim of this systematic review was to evaluate the clinical outcome of BM-MNCs transplant in SCI. The outcome measures

![Forest Plot for Overall Percentage of Patient Improved ASIA Scale](image_url)

![Forest Plot for Overall Percentage of Patients with ASIA-A Improved ASIA Scale](image_url)
were to obtain improvement in ASIA scale. The overall percentage of improvement between 328 patients was 43%. There was a considerable heterogeneity among these studies $I^2=83.6\%$ (Fig. 2). Meta-analysis was performed for each subgroup to achieve better results. Clinical outcome in patients who had ASIA scales A and B showed that the percentage of improvement in patients who had ASIA scale A at baseline (41%) was more than ASIA scale B (37%) (Table 2). Considerable differences between the number of patients in the subgroups of ASIA-A and ASIA-B might have
led to this result because the likelihood of improvement in patients with incomplete impairment should be more than the complete functional impairment (19). In addition, there was homogeneity between the studies that included patients with ASIA-B at baseline in contrast with studies that included ASIA-A at baseline (Figs. 3, 4). In comparison with the cervical and lumbar segment, cell transplantation in a thoracic segment might be less likely to affect a significant outcome. However, the potential risk of adverse effects which may result from the manipulation of cervical and lumbar spinal cord regions is higher. Therefore, a potential trial should weigh the ad-
The included trials in this review did not consider quality assessment or blinded assessments, and we did not consider safety concerns in most of phase I/II trials. The result of the meta-analysis revealed a considerable heterogeneity in both groups (Figs. 6, 7). In addition, improvement in ASIA scale occurred in the patients with thoracic level (50%) more than cervical level (43%) (Table 2), and this may be due to the higher number of thoracic cases in this review. To assess the potentially beneficial effects of experimental treatments in SCI trials, mean changes in motor and sensory scores can be a more reliable efficacy index than the conversion of ASIA scale (21). In our review, just three out of eight studies (10, 14, 16) reported the details of ASIA motor and sensory scores. Although the percentage of patients with improved ASIA scores were 10% in one of these studies (16), the pooled mean change of motor, light touch and Pinprick scores in patients of this study significantly increased after intervention (Table 3). Another clinical trial assessed the quality of life score as Barthel Index. Geffner et al. (14) investigated different routes of transplant directly into the spinal cord, the spinal canal and intravenously and observed improvements in Barthel Index of all the patients. Considering the fact that the quality of life assessment in spinal cord injury is significant, it might be helpful to use this tool as a secondary outcome (19). The authors suggest that quality of life assessment be considered as a generic outcome for SCI cell transplantation trials. Only in one clinical trial a control group was included. In this trial, the intervention group demonstrated more improvement in ASIA scale than the control group. Yoon and colleagues (17) regarded 13 patients treated with conventional decompression and fusion surgery as the control group. In this trial, 20% of the treatment group and 7% of the control patients indicated an improved neurological function. Co-administration of granulocyte macrophage-colony stimulating factor (GM-CSF) has been applied in two studies. Yoon et al. (17) stated that the administration of GM-CSF for SCI patients may result in the progression of neurologic functions without any adverse effect. Recently, several researchers revealed that GM-CSF stimulates microglial cells to produce neurotrophic cytokines such as BDNF (22). In addition, Park and colleagues (20) believed that GM-CSF enhances the activity of the patients’ bone marrow and increases the number of BM derived stem cells in the circulating peripheral blood. However, GM-CSF administration induced fever, pain and leukocytosis in this trial. Regarding dynamic pathophysiological and multifactorial nature of SCI and its consequences, the success of future cell therapy might likely depend on the informed co-administration of combinatorial stem cell transplantation, pharmacological and rehabilitation therapies (4). This review demonstrated that BM-MNCs transplantation is a relatively safe intervention without serious adverse events. In comparison with mesenchymal stem cells or other cell types, BM-MNCs can be easily obtained and isolated in a short time just before transplantation and do not require in vitro expansion. This reduces processing costs and minimizes the risks of contamination (23). The authors suggest that quality of life assessment be considered as a generic outcome for SCI cell transplantation trials. Only in one clinical trial a control group was included. In this trial, the intervention group demonstrated more improvement in ASIA scale than the control group. Yoon and colleagues (17) regarded 13 patients treated with conventional decompression and fusion surgery as the control group. In this trial, 20% of the treatment group and 7% of the control patients indicated an improved neurological function. Co-administration of granulocyte macrophage-colony stimulating factor (GM-CSF) has been applied in two studies. Yoon et al. (17) stated that the administration of GM-CSF for SCI patients may result in the progression of neurologic functions without any adverse effect. Recently, several researchers revealed that GM-CSF stimulates microglial cells to produce neurotrophic cytokines such as BDNF (22). In addition, Park and colleagues (20) believed that GM-CSF enhances the activity of the patients’ bone marrow and increases the number of BM derived stem cells in the circulating peripheral blood. However, GM-CSF administration induced fever, pain and leukocytosis in this trial. Regarding dynamic pathophysiological and multifactorial nature of SCI and its consequences, the success of future cell therapy might likely depend on the informed co-administration of combinatorial stem cell transplantation, pharmacological and rehabilitation therapies (4). This review demonstrated that BM-MNCs transplantation is a relatively safe intervention without serious adverse events. In comparison with mesenchymal stem cells or other cell types, BM-MNCs can be easily obtained and isolated in a short time just before transplantation and do not require in vitro expansion. This reduces processing costs and minimizes the risks of contamination (23). The authors suggest that quality of life assessment be considered as a generic outcome for SCI cell transplantation trials. Only in one clinical trial a control group was included. In this trial, the intervention group demonstrated more improvement in ASIA scale than the control group. Yoon and colleagues (17) regarded 13 patients treated with conventional decompression and fusion surgery as the control group. In this trial, 20% of the treatment group and 7% of the control patients indicated an improved neurological function. Co-administration of granulocyte macrophage-colony stimulating factor (GM-CSF) has been applied in two studies. Yoon et al. (17) stated that the administration of GM-CSF for SCI patients may result in the progression of neurologic functions without any adverse effect. Recently, several researchers revealed that GM-CSF stimulates microglial cells to produce neurotrophic cytokines such as BDNF (22). In addition, Park and colleagues (20) believed that GM-CSF enhances the activity of the patients’ bone marrow and increases the number of BM derived stem cells in the circulating peripheral blood. However, GM-CSF administration induced fever, pain and leukocytosis in this trial. Regarding dynamic pathophysiological and multifactorial nature of SCI and its consequences, the success of future cell therapy might likely depend on the informed co-administration of combinatorial stem cell transplantation, pharmacological and rehabilitation therapies (4). This review demonstrated that BM-MNCs transplantation is a relatively safe intervention without serious adverse events. In comparison with mesenchymal stem cells or other cell types, BM-MNCs can be easily obtained and isolated in a short time just before transplantation and do not require in vitro expansion. This reduces processing costs and minimizes the risks of contamination (23). The authors suggest that quality of life assessment be considered as a generic outcome for SCI cell transplantation trials. Only in one clinical trial a control group was included. In this trial, the intervention group demonstrated more improvement in ASIA scale than the control group. Yoon and colleagues (17) regarded 13 patients treated with conventional decompression and fusion surgery as the control group. In this trial, 20% of the treatment group and 7% of the control patients indicated an improved neurological function. Co-administration of granulocyte macrophage-colony stimulating factor (GM-CSF) has been applied in two studies. Yoon et al. (17) stated that the administration of GM-CSF for SCI patients may result in the progression of neurologic functions without any adverse effect. Recently, several researchers revealed that GM-CSF stimulates microglial cells to produce neurotrophic cytokines such as BDNF (22). In addition, Park and colleagues (20) believed that GM-CSF enhances the activity of the patients’ bone marrow and increases the number of BM derived stem cells in the circulating peripheral blood. However, GM-CSF administration induced fever, pain and leukocytosis in this trial. Regarding dynamic pathophysiological and multifactorial nature of SCI and its consequences, the success of future cell therapy might likely depend on the informed co-administration of combinatorial stem cell transplantation, pharmacological and rehabilitation therapies (4). This review demonstrated that BM-MNCs transplantation is a relatively safe intervention without serious adverse events. In comparison with mesenchymal stem cells or other cell types, BM-MNCs can be easily obtained and isolated in a short time just before transplantation and do not require in vitro expansion. This reduces processing costs and minimizes the risks of contamination (23). The authors suggest that quality of life assessment be considered as a generic outcome for SCI cell transplantation trials. Only in one clinical trial a control group was included. In this trial, the intervention group demonstrated more improvement in ASIA scale than the control group. Yoon and colleagues (17) regarded 13 patients treated with conventional decompression and fusion surgery as the control group. In this trial, 20% of the treatment group and 7% of the control patients indicated an improved neurological function. Co-administration of granulocyte macrophage-colony stimulating factor (GM-CSF) has been applied in two studies. Yoon et al. (17) stated that the administration of GM-CSF for SCI patients may result in the progression of neurologic functions without any adverse effect. Recently, several researchers revealed that GM-CSF stimulates microglial cells to produce neurotrophic cytokines such as BDNF (22). In addition, Park and colleagues (20) believed that GM-CSF enhances the activity of the patients’ bone marrow and increases the number of BM derived stem cells in the circulating peripheral blood. However, GM-CSF administration induced fever, pain and leukocytosis in this trial. Regarding dynamic pathophysiological and multifactorial nature of SCI and its consequences, the success of future cell therapy might likely depend on the informed co-administration of combinatorial stem cell transplantation, pharmacological and rehabilitation therapies (4). This review demonstrated that BM-MNCs transplantation is a relatively safe intervention without serious adverse events. In comparison with mesenchymal stem cells or other cell types, BM-MNCs can be easily obtained and isolated in a short time just before transplantation and do not require in vitro expansion. This reduces processing costs and minimizes the risks of contamination (23).
ments, and this might have led to an over-estimation of the overall outcome (24). Although the quality assessment of the trial tools presented good correlation, the results of one study which evaluated the impact of quality assessment in the meta-analysis showed that in systematic reviews with the same direction of effect, the quality assessment may not significantly change the results (25). Since most of the included studies in this review demonstrated some degrees of improvement, waiving the quality of trials may not cause significant changes.

**Conclusion**

BM-MNCs transplantation in spinal cord injury seems to be feasible, safe and have a good degree of outcome improvement. Although most of the studies showed promising results, more qualified randomized controlled trials should be conducted to examine the efficacy and appropriate dosage of BM-MNCs for patients with spinal cord injuries.

**Acknowledgments**

The authors are grateful to Dr. Manuela Joore and H. Van. Santbrink for their useful advices.

**Conflict of interests**

Authors declare they have no conflict of interests.

**References**

1. Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 1995; 5(4):407-13.
2. Stojkovic M. Stem cells and spinal cord injury. Journal of the Serbian Society for Computational Mechanics 2011; 5(2):17-23.
3. Vipond N, Zhang J. Stem cell Transplantation for Spinal Cord Injury. Evidence Based Healthcare Advisory Group, 2007:1-21.
4. Fehlings MG, Vawda R. Cellular Treatments for Spinal Cord Injury: The Time is Right for Clinical Trials. Neurotherapeutics 2011; 8(4):704-20.
5. Regenberg AC, Hutchinson LA, Schanker B, Mathews DJ. Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence. Stem Cells 2009;27(9):2312-9.
6. Moazzami K, Majdizadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database of Systematic Reviews 2011; 12: Art. No.: CD008347. DOI:10.1002/ 146 518 58.CD008347.pub2.
7. Cox Jr CS, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery. 2011;68(3):588-600.
8. Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des 2005:11(10):1255-65.
9. Dasari VR, Spomar DG, Cady C, Gujrati M, Rao JS, Dinh DH. Mesenchymal stem cells from rat bone marrow down regulate Caspase-3 mediated apoptotic pathway after spinal cord injury in rats. Neurochem Res 2007;32(12): 2080-93.
10. Park HC, Shim YS, Ha Y, et al. Treatment of Complete Spinal Cord Injury Patients by Autologous Bone Marrow Cell Transplantation and Administration of Granulocyte-Macrophage Colony Stimulating Factor. Tissue Eng 2005;11(5-6):913-22.
11. Jung JK, Oh CH, Yoon SH, Ha Y, Park S, Choi B. Outcome Evaluation with Signal Activation of Functional MRI in Spinal Cord Injury. J Korean Neurosurg Soc. 2011;50(3):209-15.
12. Attar A, Ayten M, Ozdemir M, et al. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy 2011; 13(1):54-60.
13. Deda H, Inci MC, Kürekçi AE, et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy 2008;10(6):565-74.
14. Geffner LF, Santacruz P, Izurieta M, Flor L, et al. Administration of Autologous Bone Marrow Stem Cells into Spinal Cord Injury Patients via Multiple Routes Is Safe and Improves Their Quality of Life: Comprehensive Case Studies. Cell Transplant 2008;17(12):1277-93.
15. Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous Bone Marrow Derived Mononuclear Cell Therapy for Spinal Cord Injury: A Phase I/II Clinical Safety and Primary Efficacy Data. Exp Clin Transplant 2009;7(4):241-8.
16. Syková E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006;15(8-9):675-87.
17. Yoon SH, Shim YS, Park YH, et al. Complete Spinal Cord Injury Treatment Using Autologous Bone Marrow Cell Transplantation and Bone Marrow Stimulation with Granulocyte Macrophage-Colony Stimulating Factor: Phase I/II Clinical Trial.
Stem Cells 2007;25(8):2066-73.
18. Tuszyński MH, Steeves JD, Fawcett JW, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 2007;45(3):222-31.
9. Steeves JD, Lammerse D, Curt A, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007; 45(3):206-21.
20. Katalinic OM, Harvey LA, Herbert RD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther 2011; 91(1): 11-24.
21. Fawcett JW, Curt A, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP Panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007;45(3):190-205.
22. Bouhy D, Malgrange B, Multon S, et al. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages. FASEB J 2006;20(8):1239-41.
23. Alvarez-Viejo M, Menendez-Menendez Y, Blanco-Gelaz M, Ferrero-Gutierrez A, Fernandez-Rodriguez M, Gala J, et al., editors. Quantifying Mesenchymal Stem Cells in the Mononuclear Cell Fraction of Bone Marrow Samples Obtained for Cell Therapy. Transplantation proceedings; 2013: Elsevier.
24. Moore A, McQuay H, Bandoli’s Little Book of Making Sense of the Medical Evidence. Oxford: Oxford University Press, 2006.
25. Carlos Rodrigues da Silva Filhoa , et al. Assessment of clinical trial quality and its impact on meta-analyses. Rev Saude publica 2005;39(6).